Scarica l'app Stockscreener
24.64
2.10%
0.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$23.84
Aprire:
$24.35
Volume 24 ore:
11,704
Relative Volume:
0.01
Capitalizzazione di mercato:
$5.00B
Reddito:
-
Utile/perdita netta:
$-464.20M
Rapporto P/E:
-9.1861
EPS:
-2.6823
Flusso di cassa netto:
$-423.09M
1 W Prestazione:
+2.92%
1M Prestazione:
-11.20%
6M Prestazione:
+49.97%
1 anno Prestazione:
+36.05%
Intervallo 1D:
$24.30
$24.61
Intervallo di 1 settimana:
$22.79
$25.17
Portata 52W:
$12.72
$29.25
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-410-3120
Indirizzo
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
24.59 | 5.04B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
452.54 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
752.21 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.05 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
691.35 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
146.63 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Mkt Perform |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Iniziato | Truist | Hold |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-03-03 | Iniziato | Jefferies | Hold |
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish - AOL.com
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? - AOL.com
Top Immunovant Executive Quietly Cashes Out in Notable Insider Stock Move - TipRanks
Immunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 2,877 Shares - MarketBeat
Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock - Investing.com
Immunovant, Inc. (IMVT) CLO sells 2,877 shares to cover RSU taxes - Stock Titan
Bernstein initiates Immunovant stock coverage with neutral rating - Investing.com UK
Bernstein initiates Immunovant stock coverage with neutral rating By Investing.com - Investing.com India
Immunovant (NASDAQ:IMVT) Now Covered by Sanford C. Bernstein - MarketBeat
Is Immunovant Gaining Fresh Momentum Across The Nasdaq 100 Index Now? - Kalkine Media
Understanding the Setup: (IMVT) and Scalable Risk - Stock Traders Daily
Immunovant shares climb 7% as fiscal Q3 loss comes in better than expected - MSN
Immunovant, Inc. $IMVT is Alpine Global Management LLC's 3rd Largest Position - MarketBeat
Immunovant, Inc. $IMVT Shares Purchased by Granahan Investment Management LLC - MarketBeat
HighVista Strategies LLC Grows Position in Immunovant, Inc. $IMVT - MarketBeat
Truist Securities Initiates Coverage of Immunovant (IMVT) with Hold Recommendation - MSN
Prosight Management LP Has $11.26 Million Stock Position in Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immunovant stock surges 17% in 3 months: What's driving it? - MSN
Immunovant, Inc. (IMVT) analysts raise price targets following Q3 earnings update - MSN
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN
The Technical Signals Behind (IMVT) That Institutions Follow - Stock Traders Daily
UBS Downgrades Immunovant (IMVT) - MSN
Immunovant Stock Surges 17% in 3 Months: What's Driving It? - TradingView
Immunovant Stock Pre-Market (+8.1%) : Key Analyst Upgrade Cites Pipeline Confidence - Trefis
Vanguard Group Inc. Has $110.05 Million Holdings in Immunovant, Inc. $IMVT - MarketBeat
TD Asset Management Inc Sells 56,752 Shares of Immunovant, Inc. $IMVT - MarketBeat
Citigroup Inc. Sells 75,860 Shares of Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update - Bitget
How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones - simplywall.st
Immunovant, Inc. (IMVT) Stock Analysis: A Compelling 48.2% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Immunovant (IMVT) COO executes 3,238-share sell-to-cover tax transaction - Stock Titan
Immunovant stock hits 52-week high at 28.32 USD By Investing.com - Investing.com Australia
Immunovant (NASDAQ:IMVT) Sets New 52-Week HighHere's What Happened - MarketBeat
Immunovant stock hits 52-week high at 28.32 USD - Investing.com
Precision Trading with Immunovant Inc. (IMVT) Risk Zones - Stock Traders Daily
Immunovant, Inc. (IMVT) Stock Analysis: Unpacking A 51% Potential Upside - DirectorsTalk Interviews
IMVT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Assessing Immunovant (IMVT) Valuation As Shares Deliver A 25% One Year Return - Yahoo Finance
What are Immunovant Inc.’s earnings expectationsOil Prices & Risk Managed Investment Strategies - mfd.ru
Aberdeen Group plc Has $15.83 Million Stock Position in Immunovant, Inc. $IMVT - MarketBeat
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Immunovant Inc. stock recover faster than marketTrade Analysis Report & Stepwise Swing Trade Plans - mfd.ru
What are analysts’ price targets for Immunovant Inc.Quarterly Trade Report & Capital Efficient Trading Techniques - mfd.ru
Technical Reactions to IMVT Trends in Macro Strategies - Stock Traders Daily
Why hedge funds are buying Immunovant Inc. stockMarket Trend Summary & Real-Time Volume Spike Alerts - mfd.ru
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunovant Inc Azioni (IMVT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gloria Melanie | Chief Operating Officer |
Feb 25 '26 |
Sale |
27.85 |
3,238 |
90,184 |
170,273 |
1.13%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):